A Phase 1 interventional study of Glucophage® XR RM Test and Glucophage® XR Reference in Healthy, sponsored by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-29.
Sponsored by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (part of Merck KGaA, Darmstadt, Germany) · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 113 studies testing metformin in Diabetes Mellitus — 7 open to participants now, 7 under way, 1 of them phase 3. Metformin · Diabetes Mellitus.
Among the 113 studies testing metformin in Diabetes Mellitus, this one is the 68th largest by enrollment of the 112 interventional ones that give a count, is one of 5 that started in 2020, is one of 15 in phase 1, and was the 103rd registered.
8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.
Browse Diabetes Mellitus studies →7 of the 113 studies testing metformin in Diabetes Mellitus are open now, in 6 countries. Recruiting first, the newest first:
Washington University School of Medicine · Sites in Nigeria
Ages 18+
Nabiqasim Industries (Pvt) Ltd · Sites in Pakistan
Ages 18–80
Boryung Pharmaceutical Co., Ltd · Sites in Korea, Republic of
Ages 19+ · Healthy volunteers
Boryung Pharmaceutical Co., Ltd · Sites in Korea, Republic of
Ages 19+ · Healthy volunteers
Ohio State University · Sites in United States
Ages 18+ · Women only
By country, each count listing its studies:
Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.
This study: 19 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
113 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 17 · Phase 3 36 · Phase 4 37
First in 1996; this study’s year is marked. 5 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 81 is close to the median of 80 across 6,025 interventional studies indexed under Diabetes Mellitus.
Median enrollment 108 across the 112 interventional studies. Of the 96 that completed or were terminated, 45 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
50 of 113 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, one of the names counted as Merck KGaA, Darmstadt, Germany. Under that name alone:
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany is the lead sponsor of 56 studies on the registry; 5 are open to participants now.
Merck KGaA, Darmstadt, Germany has 8 studies filed under Diabetes Mellitus — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 113 studies testing metformin in Diabetes Mellitus, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to assess bioequivalence (BE) of newly developed Glucophage® XR (GXR) reduced mass (RM) tablet (metformin hydrochloride 500 milligrams (mg) test tablet) and marketed Glucophage ® XR tablet (metformin hydrochloride 500 mg reference tablet) following single oral dose administration under fasted and fed conditions by comparing pharmacokinetics, safety and tolerability between test and reference in healthy participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a single oral dose of 500 milligram (mg) of reference GXR (Glucophage® Extended Release) tablet on Day 1 in treatment period 1 followed by single oral dose of 500 mg test GXR RM (Reduced Mass) tablet on Day 8 in treatment period 2 under fasting conditions. There was a washout period of 7 days between two treatment period.
Drug: Glucophage® XR RM Test · Drug: Glucophage® XR Reference
Participants received a single oral dose of 500 milligrams (mg) of test GXR RM tablet on Day 1 in treatment period 1 followed by single oral dose of 500 mg of reference GXR tablet on Day 8 in treatment period 2 under fasting conditions. There was a washout period of 7 days between two treatment period.
Drug: Glucophage® XR RM Test · Drug: Glucophage® XR Reference
Participants received a single oral dose of 500 milligrams (mg) of reference GXR tablet on Day 1 in treatment period 1 followed by single oral dose of 500 mg of test GXR RM tablet on Day 8 in treatment period 2 under fed conditions. There was a washout period of 7 days between two treatment period.
Drug: Glucophage® XR RM Test · Drug: Glucophage® XR Reference
Participants received a single oral dose of 500 milligrams (mg) of test GXR RM tablet on Day 1 in treatment period 1 followed by single oral dose of 500 mg of reference GXR tablet on Day 8 in treatment period 2 under fed conditions. There was a washout period of 7 days between two treatment period.
Drug: Glucophage® XR RM Test · Drug: Glucophage® XR Reference
Participants received a single oral dose of 500 mg of test Glucophage® XR RM tablet under fasting or fed conditions.
Also known as: Metformin hydrochloride
Participants received a single oral dose of 500 mg of reference Glucophage® XR tablet under fasting or fed conditions.
Also known as: Metformin hydrochloride
Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUClast) of Metformin
Area under the plasma concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule.
Time frame: Part 1 (fasted): Pre-dose and 0.5, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 24 and 32 hours post dose. Part 2 (fed): Pre-dose 1, 2, 3, 4, 5, 5.5, 6, 6.5, 7, 8, 9, 10, 12, 24 and 32 hours post dose
Maximum Observed Plasma Concentration (Cmax) of Metformin
Cmax was obtained directly from the concentration versus time curve.
Time frame: Part 1 (fasted): Pre-dose and 0.5, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 24 and 32 hours post dose. Part 2 (fed): Pre-dose 1, 2, 3, 4, 5, 5.5, 6, 6.5, 7, 8, 9, 10, 12, 24 and 32 hours post dose
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs
An Adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease associated with the use of study drug, whether or not considered related to the study drug or worsening of pre-existing medical condition, whether or not related to study drug. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. An AE was considered as 'treatment emergent' if it occurred after the first drug administration of each period or if it was present prior to drug administration but exacerbated after the drug administration. TEAEs included both Serious TEAEs and non-serious TEAEs.
Time frame: From Day 1 up to 3 weeks
Number of Participants Taking Concomitant Medications
Concomitant medications included medications administered from the first administration of study interventions to the end of observation.
Time frame: From Day 1 up to 3 weeks
Number of Participants With Clinically Significant Change From Baseline in Laboratory Values
The laboratory measurements included hematology, blood chemistry, urinalysis and Blood Sugar Test (BST). Number of participants with clinically significant changes from baseline in laboratory values were reported. Clinically Significance was decided by investigator.
Time frame: From Day1 (baseline) up to 3 weeks
Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiogram (ECG) Findings
The 12-lead ECG recordings were obtained after 5 minutes of rest in a semi-supine position. ECG recordings included rhythm, ventricular rate, PR interval, QRS duration, QT and QTc intervals. Number of participants with clinically significant changes from baseline in 12-lead ECG findings were reported. Clinically significance was decided by investigator.
Time frame: From Day 1 (baseline) up to 3 weeks
Number of Participants With Clinically Significant Change From Baseline in Vital Signs
Vital sign assessment included blood pressure, pulse rate, body temperature and respiration rate. Number of participants with clinically significant changes from baseline in vital signs were reported. Clinically significance was decided by investigator.
Time frame: From Day 1 (baseline) up to 3 weeks
Number of Participants With Clinically Significant Change From Baseline in Physical Examination Findings
Physical examination included assessments of the skin, lungs, cardiovascular system, abdomen (liver and spleen), and the symptoms reported by the participant. Number of participants with clinically significant changes from baseline in vital signs were reported. Clinically significance was decided by investigator.
Time frame: From Day 1 (baseline) up to 3 weeks
Area Under Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Metformin
AUC0-inf was calculated by combining AUC0-t and AUC extra. AUC extra represents an extrapolated value obtained by Clast/ lambda z, where Clast is the calculated plasma concentration at the last sampling time point at which the measured plasma concentration is at or above the Lower Limit of quantification (LLQ) and lambda z is the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.
Time frame: Part 1 (fasted): Pre-dose and 0.5, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 24 and 32 hours post dose. Part 2 (fed): Pre-dose 1, 2, 3, 4, 5, 5.5, 6, 6.5, 7, 8, 9, 10, 12, 24 and 32 hours post dose
Ratio of Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC0-tlast) to Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Metformin
The ratio of AUClast to AUCinf were reported.
Time frame: Part 1 (fasted): Pre-dose and 0.5, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 24 and 32 hours post dose. Part 2 (fed): Pre-dose 1, 2, 3, 4, 5, 5.5, 6, 6.5, 7, 8, 9, 10, 12, 24 and 32 hours post dose
Apparent Terminal Half-Life (t1/2) of Metformin
Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by lambda z.
Time frame: Part 1 (fasted): Pre-dose and 0.5, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 24 and 32 hours post dose. Part 2 (fed): Pre-dose 1, 2, 3, 4, 5, 5.5, 6, 6.5, 7, 8, 9, 10, 12, 24 and 32 hours post dose
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Metformin
Time to reach the maximum plasma concentration (Tmax) was obtained directly from the concentration versus time curve.
Time frame: Part 1 (fasted): Pre-dose and 0.5, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 24 and 32 hours post dose. Part 2 (fed): Pre-dose 1, 2, 3, 4, 5, 5.5, 6, 6.5, 7, 8, 9, 10, 12, 24 and 32 hours post dose
A total of 56 participants were screened for the study in Part 1 (Fasted state) out of which 48 were randomized. For Part 2 (Fed state), a total of 49 participants were screened out of which 33 were randomized.
| Milestone | First Reference GXR (Fasting), Then Test GXR RM Tablet (Fasting) | First Test GXR RM (Fasting), Then Reference GXR (Fasting) | First Reference GXR (Fed), Then Test GXR RM (Fed) | First Test GXR RM (Fed), Then Reference GXR (Fed) |
|---|---|---|---|---|
| Started | 24 | 24 | 17 | 16 |
| Completed | 24 | 23 | 15 | 15 |
| Not completed | 0 | 1 | 2 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 2 | 1 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 |
| Milestone | First Reference GXR (Fasting), Then Test GXR RM Tablet (Fasting) | First Test GXR RM (Fasting), Then Reference GXR (Fasting) | First Reference GXR (Fed), Then Test GXR RM (Fed) | First Test GXR RM (Fed), Then Reference GXR (Fed) |
|---|---|---|---|---|
| Started | 24 | 23 | 15 | 15 |
| Completed | 24 | 23 | 15 | 15 |
| Not completed | 0 | 0 | 0 | 0 |
Area under the plasma concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule.
| hour*nanogram per milliter (hr*ng/ml) | Reference GXR (Fasting) | Test GXR RM (Fasting) | Reference GXR (Fed) | Test GXR RM (Fed) |
|---|---|---|---|---|
| Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUClast) of Metformin | 3627.171 ± 31.9 | 4076.521 ± 30.4 | 6981.833 ± 18.1 | 6564.938 ± 26.4 |
Cmax was obtained directly from the concentration versus time curve.
| nanogram per milliliter (ng/mL) | Reference GXR (Fasting) | Test GXR RM (Fasting) | Reference GXR (Fed) | Test GXR RM (Fed) |
|---|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Metformin | 605.347 ± 31.7 | 677.651 ± 31.2 | 590.956 ± 18.9 | 671.864 ± 16.7 |
An Adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease associated with the use of study drug, whether or not considered related to the study drug or worsening of pre-existing medical condition, whether or not related to study drug. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. An AE was considered as 'treatment emergent' if it occurred after the first drug administration of each period or if it was present prior to drug administration but exacerbated after the drug administration. TEAEs included both Serious TEAEs and non-serious TEAEs.
| Participants | Reference GXR (Fasting) | Test GXR RM (Fasting) | Reference GXR (Fed) | Test GXR RM (Fed) |
|---|---|---|---|---|
| TEAEs | 7 | 7 | 3 | 2 |
| Serious TEAEs | 0 | 0 | 0 | 0 |
Concomitant medications included medications administered from the first administration of study interventions to the end of observation.
| Participants | Reference GXR (Fasting) | Test GXR RM (Fasting) | Reference GXR (Fed) | Test GXR RM (Fed) |
|---|---|---|---|---|
| Number of Participants Taking Concomitant Medications | 0 | 0 | 0 | 0 |
The laboratory measurements included hematology, blood chemistry, urinalysis and Blood Sugar Test (BST). Number of participants with clinically significant changes from baseline in laboratory values were reported. Clinically Significance was decided by investigator.
| Participants | Reference GXR (Fasting) | Test GXR RM (Fasting) | Reference GXR (Fed) | Test GXR RM (Fed) |
|---|---|---|---|---|
| Hematology | 0 | 0 | 0 | 0 |
| Biochemistry | 0 | 0 | 0 | 0 |
| Urinalysis | 0 | 0 | 0 | 0 |
| Blood Sugar Test (BST) | 0 | 0 | 0 | 0 |
The 12-lead ECG recordings were obtained after 5 minutes of rest in a semi-supine position. ECG recordings included rhythm, ventricular rate, PR interval, QRS duration, QT and QTc intervals. Number of participants with clinically significant changes from baseline in 12-lead ECG findings were reported. Clinically significance was decided by investigator.
| Participants | Reference GXR (Fasting) | Test GXR RM (Fasting) | Reference GXR (Fed) | Test GXR RM (Fed) |
|---|---|---|---|---|
| Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiogram (ECG) Findings | 0 | 0 | 0 | 0 |
Vital sign assessment included blood pressure, pulse rate, body temperature and respiration rate. Number of participants with clinically significant changes from baseline in vital signs were reported. Clinically significance was decided by investigator.
| Participants | Reference GXR (Fasting) | Test GXR RM (Fasting) | Reference GXR (Fed) | Test GXR RM (Fed) |
|---|---|---|---|---|
| Number of Participants With Clinically Significant Change From Baseline in Vital Signs | 0 | 0 | 0 | 0 |
Physical examination included assessments of the skin, lungs, cardiovascular system, abdomen (liver and spleen), and the symptoms reported by the participant. Number of participants with clinically significant changes from baseline in vital signs were reported. Clinically significance was decided by investigator.
| Participants | Reference GXR (Fasting) | Test GXR RM (Fasting) | Reference GXR (Fed) | Test GXR RM (Fed) |
|---|---|---|---|---|
| Number of Participants With Clinically Significant Change From Baseline in Physical Examination Findings | 0 | 0 | 0 | 0 |
AUC0-inf was calculated by combining AUC0-t and AUC extra. AUC extra represents an extrapolated value obtained by Clast/ lambda z, where Clast is the calculated plasma concentration at the last sampling time point at which the measured plasma concentration is at or above the Lower Limit of quantification (LLQ) and lambda z is the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.
| hr*ng/ml | Reference GXR (Fasting) | Test GXR RM (Fasting) | Reference GXR (Fed) | Test GXR RM (Fed) |
|---|---|---|---|---|
| Area Under Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Metformin | 3911.152 ± 30.8 | 4370.051 ± 28.6 | 7297.899 ± 16.4 | 6833.321 ± 23.6 |
The ratio of AUClast to AUCinf were reported.
| Ratio | Reference GXR (Fasting) | Test GXR RM (Fasting) | Reference GXR (Fed) | Test GXR RM (Fed) |
|---|---|---|---|---|
| Ratio of Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC0-tlast) to Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Metformin | 0.927 ± 4.7 | 0.933 ± 3.2 | 0.953 ± 9.9 | 0.961 ± 3.5 |
Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by lambda z.
| hours | Reference GXR (Fasting) | Test GXR RM (Fasting) | Reference GXR (Fed) | Test GXR RM (Fed) |
|---|---|---|---|---|
| Apparent Terminal Half-Life (t1/2) of Metformin | 3.520 ± 60.1 | 3.769 ± 47.1 | 4.122 ± 19.5 | 3.386 ± 21.1 |
Time to reach the maximum plasma concentration (Tmax) was obtained directly from the concentration versus time curve.
| hours | Reference GXR (Fasting) | Test GXR RM (Fasting) | Reference GXR (Fed) | Test GXR RM (Fed) |
|---|---|---|---|---|
| Time to Reach Maximum Observed Plasma Concentration (Tmax) of Metformin | 3.500 (2.000 to 5.000) | 3.500 (1.000 to 5.000) | 5.500 (4.000 to 10.000) | 5.010 (5.000 to 8.000) |
Collected over From informed consent (Day-28 to Day-2) up to 3 weeks, a maximum of 49 days.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Reference GXR (Fasting) | 0/47 (0%) | 0/47 (0%) | 7/47 (14.9%) |
| Test GXR RM (Fasting) | 0/48 (0%) | 0/48 (0%) | 7/48 (14.6%) |
| Reference GXR (Fed) | 0/32 (0%) | 0/32 (0%) | 3/32 (9.4%) |
| Test GXR RM (Fed) | 0/31 (0%) | 0/31 (0%) | 2/31 (6.5%) |
| Event | Reference GXR (Fasting) | Test GXR RM (Fasting) | Reference GXR (Fed) | Test GXR RM (Fed) |
|---|---|---|---|---|
| Electrocardiogram PR prolongationInvestigations | 3/47 | 2/48 | 0/32 | 1/31 |
| Electrocardiogram QT prolongedInvestigations | 0/47 | 0/48 | 2/32 | 0/31 |
| Human chorionic gonadotropin increasedInvestigations | 2/47 | 0/48 | 0/32 | 0/31 |
| White blood cells urine positiveInvestigations | 2/47 | 2/48 | 1/32 | 1/31 |
| PresyncopeNervous system disorders | 0/47 | 2/48 | 0/32 | 0/31 |
| White blood cell count increasedInvestigations | 0/47 | 0/48 | 0/32 | 1/31 |
| Blood creatine phosphokinase increasedInvestigations | 1/47 | 1/48 | 0/32 | 0/31 |
| Alanine aminotransferase increasedInvestigations | 1/47 | 0/48 | 0/32 | 0/31 |
| Aspartate aminotransferase increasedInvestigations | 1/47 | 0/48 | 0/32 | 0/31 |
| Blood creatinine increasedInvestigations | 1/47 | 1/48 | 0/32 | 0/31 |
Demographic population included all those participants who participated in the bioequivalence study (that is all participants who were randomized)
| Age, Categorical(Participants) | First Reference GXR (Fasting), Then Test GXR RM (Fasting) | First Test GXR RM (Fasting), Then Reference GXR (Fasting) | First Reference GXR (Fed), Then Test GXR RM (Fed) | First Test GXR RM (Fed), Then Reference GXR (Fed) | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 24 | 24 | 17 | 16 | 81 |
| >=65 years | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | First Reference GXR (Fasting), Then Test GXR RM (Fasting) | First Test GXR RM (Fasting), Then Reference GXR (Fasting) | First Reference GXR (Fed), Then Test GXR RM (Fed) | First Test GXR RM (Fed), Then Reference GXR (Fed) | Total |
|---|---|---|---|---|---|
| Female | 7 | 7 | 5 | 3 | 22 |
| Male | 17 | 17 | 12 | 13 | 59 |
| Race (NIH/OMB)(Participants) | First Reference GXR (Fasting), Then Test GXR RM (Fasting) | First Test GXR RM (Fasting), Then Reference GXR (Fasting) | First Reference GXR (Fed), Then Test GXR RM (Fed) | First Test GXR RM (Fed), Then Reference GXR (Fed) | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 24 | 24 | 17 | 16 | 81 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — We are committed to enhancing public health through responsible sharing of clinical trial data. Following approval of a new product or a new indication for an approved product in both the US and the European Union, the study sponsor and/or its affiliated companies will share study protocols, anonymized patient data and study level data, and redacted clinical study reports with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website https://bit.ly/IPD21
Ran from Dec 2020 to primary completion in Mar 2022, 14 months.
Results were first posted in Dec 2023, 1 year 9 months after primary completion.
Of 171 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 10. This study's 14 months is above that.
Counting every sponsor, half of 247 studies reached it within 7 months; a quarter within 3 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Metformin
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany →